全文获取类型
收费全文 | 807篇 |
免费 | 62篇 |
国内免费 | 10篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 17篇 |
妇产科学 | 17篇 |
基础医学 | 90篇 |
口腔科学 | 8篇 |
临床医学 | 88篇 |
内科学 | 279篇 |
皮肤病学 | 7篇 |
神经病学 | 25篇 |
特种医学 | 13篇 |
外科学 | 57篇 |
综合类 | 18篇 |
预防医学 | 116篇 |
眼科学 | 7篇 |
药学 | 80篇 |
中国医学 | 10篇 |
肿瘤学 | 44篇 |
出版年
2023年 | 10篇 |
2022年 | 32篇 |
2021年 | 44篇 |
2020年 | 24篇 |
2019年 | 36篇 |
2018年 | 27篇 |
2017年 | 20篇 |
2016年 | 16篇 |
2015年 | 23篇 |
2014年 | 30篇 |
2013年 | 39篇 |
2012年 | 52篇 |
2011年 | 53篇 |
2010年 | 39篇 |
2009年 | 21篇 |
2008年 | 49篇 |
2007年 | 36篇 |
2006年 | 47篇 |
2005年 | 55篇 |
2004年 | 25篇 |
2003年 | 23篇 |
2002年 | 27篇 |
2001年 | 15篇 |
2000年 | 13篇 |
1999年 | 12篇 |
1998年 | 13篇 |
1997年 | 10篇 |
1996年 | 4篇 |
1995年 | 6篇 |
1994年 | 3篇 |
1993年 | 4篇 |
1992年 | 12篇 |
1991年 | 8篇 |
1990年 | 6篇 |
1989年 | 8篇 |
1988年 | 13篇 |
1987年 | 5篇 |
1986年 | 5篇 |
1985年 | 3篇 |
1984年 | 3篇 |
1983年 | 1篇 |
1980年 | 1篇 |
1978年 | 1篇 |
1977年 | 2篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有879条查询结果,搜索用时 31 毫秒
41.
42.
Luo D Liu QF Gove C Naomov N Su JJ Williams R 《World journal of gastroenterology : WJG》1998,4(2):97-99
AIM:To study the relationship between N-ras gene mutation and p53 gene expression in the carcinogenesis and the development of human hepatocellular carcinomas (HCC).METHODS:The N-ras gene mutation and the p53 gene expression were analyzed in 29 cases of HCC by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and immunohistochemistry.RESULTS:Thirteen cases of HCCs were p53 positive (44.8%), which showed a rather high Cpercen-tage of p53 gene mutation in Guangxi. The aberrations at N-ras codon 2-37 were found in 79.31% of HCCs and 80.77% of adjacent non-tumorous liver tissues. More than 2 point mutations of N-ras gene were observed in 22 cases (75.86%). Twelve cases (41.37%) of HCCs showed both N-ras gene mutation and p53 gene expression.CONCLUSION:N-ras gene and p53 gene may be involved in the carcinogenesis and the development of HCC.That 38% of HCCs with N-ras gene mutation did not express p53 protein indicates that some other genes or factors may participate in the carcinogenesis and the development of HCC. 相似文献
43.
Nguyen Van Hong Alfred Amambua-Ngwa Nguyen Quang Tuan Do Duy Cuong Nguyen Thi Huong Giang Nguyen Van Dung Ta Thi Tinh Nguyen Van Tien Bui Quang Phuc Tran Thanh Duong Anna Rosanas-Urgell Umberto D’Alessandro Jean-Pierre Van Geertruyden Annette Erhart 《Emerging infectious diseases》2014,20(7):1207-1210
Resistance to artemisinin derivatives, the most potent antimalarial drugs currently used, has emerged in Southeast Asia and threatens to spread to Africa. We report a case of malaria in a man who returned to Vietnam after 3 years in Angola that did not respond to intravenous artesunate and clindamycin or an oral artemisinin-based combination. 相似文献
44.
45.
46.
Brendan Flannery Swathi N. Thaker Jessie Clippard Arnold S. Monto Suzanne E. Ohmit Richard K. Zimmerman Mary Patricia Nowalk Manjusha Gaglani Michael L. Jackson Lisa A. Jackson Edward A. Belongia Huong Q. McLean LaShondra Berman Angie Foust Wendy Sessions Sarah Spencer Alicia M. Fry 《MMWR. Morbidity and mortality weekly report》2014,63(7):137-142
47.
Tran Hien Nguyen Minh Huong Vu Van Cuong Nguyen Lien Huong Nguyen Kohei Toda Tuyet Nga Nguyen Sang Dao Kathleen A. Wannemuehler Karen A. Hennessey 《Vaccine》2014
Background
Vietnam has high endemic hepatitis B virus infection with >8% of adults estimated to have chronic infection. Hepatitis B vaccine was first introduced in the national childhood immunization program in 1997 in high-risk areas, expanded nationwide in 2002, and included birth dose vaccination in 2003. This survey aimed to assess the impact of Vietnam's vaccination programme by estimating the prevalence of hepatitis B surface antigen (HBsAg) among children born during 2000–2008.Methods
This nationally representative cross-sectional survey sampled children based on a stratified three-stage cluster design. Demographic and vaccination data were collected along with a whole blood specimen that was collected and interpreted in the field with a point-of-care HBsAg test.Results
A total of 6,949 children were included in the survey analyses. The overall HBsAg prevalence among surveyed children was 2.70% (95% confidence interval (CI): 2.20–3.30). However, HBsAg prevalence was significantly higher among children born in 2000–2003 (3.64%) compared to children born 2007–2008 (1.64%) (prevalence ratio (PR: 2.22, CI 1.55–3.18)). Among all children included in the survey, unadjusted HBsAg prevalence among children with ≥3 doses of hepatitis B vaccine including a birth dose (1.75%) was significantly lower than among children with ≥3 doses of hepatitis B vaccine but lacked a birth dose (2.98%) (PR: 1.71, CI: 1.00–2.91) and significantly lower than among unvaccinated children (3.47%) (PR: 1.99, CI: 1.15–3.45). Infants receiving hepatitis B vaccine >7 days after birth had significantly higher HBsAg prevalence (3.20%) than those vaccinated 0-1 day after birth (1.52%) (PR: 2.09, CI: 1.27–3.46).Conclusion
Childhood chronic HBV infection prevalence has been markedly reduced in Vietnam due to vaccination. Further strengthening of timely birth dose vaccination will be important for reducing chronic HBV infection prevalence of under 5 children to <1%, a national and Western Pacific regional hepatitis B control goal. 相似文献48.
49.
Nghiem Nguyet Thu Truong Tuyet Mai Tran Th໋ Thu Trang Nguyen Anh Tuan Tran Chau Quyen Nguyen Lien Hanh Nguyen Huu Hoan Bui Thi Huong Lan Phung Thi Hau Ha Huy Tue Truong Viet Dung Ryohei Tsuji Yuta Watanabe Naoki Yamamoto Osamu Kanauchi 《Nutrients》2022,14(3)
Lactococcus lactis strain Plasma (LC-Plasma) is reported to have anti-viral effects via direct activation of plasmacytoid dendritic cells, which upregulate the production of type I and III interferons. A randomized, placebo-controlled, double-blind, parallel group study was designed for elementary schoolchildren, grades 1 to 3, in Vietnam. LC-Plasma or a control were administered to schoolchildren as a beverage (1.0 × 1011 count LC-Plasma/day/person). The primary endpoint was to determine the efficacy of LC-Plasma in reducing the cumulative days absent from school due to upper respiratory disease (URID) and gastrointestinal disease (GID), and the secondary endpoint was to evaluate the potency of LC-Plasma on URID/GID symptoms and general well-being scores. LC-Plasma intake significantly reduced the cumulative days absent from school due to URID/GID (Odds ratio (OR) = 0.57, p = 0.004) and URID alone (OR = 0.56, p = 0.005); LC-Plasma also significantly reduced the number of cumulative fever positive days during the first 4 weeks of intervention (OR = 0.58, p = 0.001) and cumulative days with diarrhea during the last 4 weeks of the intervention period (OR = 0.78, p = 0.01). The number of positive general wellbeing days was significantly improved in the LC-Plasma group compared with the control throughout the intervention period (OR = 0.93, 0.93, p = 0.03, 0.04 in the first and last 4 weeks of the intervention, respectively). These data suggest that LC-Plasma seems to improve the health condition of elementary schoolchildren and reduces school absenteeism due to infectious disease, especially URID. 相似文献
50.
Nguyen Minh Tam Minh Quan Pham Nguyen Xuan Ha Pham Cam Nam Huong Thi Thu Phung 《RSC advances》2021,11(28):17478
The coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread worldwide recently, leading to global social and economic disruption. Although the emergently approved vaccine programs against SARS-CoV-2 have been rolled out globally, the number of COVID-19 daily cases and deaths has remained significantly high. Here, we attempt to computationally screen for possible medications for COVID-19 via rapidly estimating the highly potential inhibitors from an FDA-approved drug database against the main protease (Mpro) of SARS-CoV-2. The approach combined molecular docking and fast pulling of ligand (FPL) simulations that were demonstrated to be accurate and suitable for quick prediction of SARS-CoV-2 Mpro inhibitors. The results suggested that twenty-seven compounds were capable of strongly associating with SARS-CoV-2 Mpro. Among them, the seven top leads are daclatasvir, teniposide, etoposide, levoleucovorin, naldemedine, cabozantinib, and irinotecan. The potential application of these drugs in COVID-19 therapy has thus been discussed.Approved drugs predicted to interact with critical residues in the substrate-binding site of SARS-CoV-2 Mpro can be promising inhibitors. 相似文献